Wedbush Estimates Adicet Bio’s FY2025 Earnings (NASDAQ:ACET)

Adicet Bio, Inc. (NASDAQ:ACET) – Analysts at Wedbush upped their FY2025 earnings per share (EPS) estimates for Adicet Bio in a research report issued on Wednesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.07) per share for the year, up from their previous estimate of ($1.20). Wedbush has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. Wedbush also issued estimates for Adicet Bio’s Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at ($0.73) EPS.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.03).

Other equities analysts have also issued research reports about the stock. Guggenheim lifted their price target on shares of Adicet Bio from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. HC Wainwright increased their target price on Adicet Bio from $4.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday. Jefferies Financial Group raised Adicet Bio to a “strong-buy” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Adicet Bio Price Performance

ACET opened at $0.64 on Monday. Adicet Bio has a 1 year low of $0.45 and a 1 year high of $1.40. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.74. The stock has a market capitalization of $53.25 million, a PE ratio of -0.51 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.62 and a current ratio of 5.62.

Institutional Trading of Adicet Bio

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC raised its stake in shares of Adicet Bio by 1.8% during the first quarter. Acadian Asset Management LLC now owns 2,039,324 shares of the company’s stock valued at $1,538,000 after purchasing an additional 36,277 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Adicet Bio by 33.3% in the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company’s stock valued at $49,000 after purchasing an additional 20,000 shares during the period. Goldman Sachs Group Inc. grew its holdings in Adicet Bio by 1.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after purchasing an additional 63,691 shares in the last quarter. Finally, Wealthedge Investment Advisors LLC increased its stake in Adicet Bio by 208.8% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 227,801 shares of the company’s stock worth $172,000 after buying an additional 154,037 shares during the period. Institutional investors and hedge funds own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.